Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open Label Study of the Effect of Daily Treatment with MPC-7869 in Subjects with Alzheimer's Disease
2007-003362-17Phase 3Active
- Sponsor
- Myrexis, Inc.
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tarenflurbil in Alzheimer's disease (AD), sponsored by Myrexis, Inc. Primary endpoint: Safety endpoints. Started Nov 2007; status: active.
02
Drugs
tarenflurbil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2007-003362-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003362-17.